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The intense infl uenza activity in England during the 
2010–11 winter resulted from a combination of factors. 
Population-based seroepidemiology confi rms that the third 
wave of infl uenza A(H1N1)pdm09 virus circulation was as-
sociated with a shift in age groups affected, with the highest 
rate of infection in young adults.
Seroepidemiologic data collected in England during the fi rst 2 infl uenza pandemic waves suggested that 
another wave of infection with infl uenza A(H1N1)pdm09 
virus was unlikely during 2010–11 (1). However, a sub-
stantial third wave occurred that affected persons in older 
age groups (2). Severity indicators suggested a higher 
level of illness and death, with increased cases in critical 
care and deaths. We conducted further seroepidemiologic 
study in England during 2010–11 to identify possible rea-
sons for these observations.
The Study
This observational study used anonymized, residual 
serum samples from routine microbiological testing. Pa-
tient age and sex, date of sample collection, and source 
laboratory information were available (3).
Samples were from patients 0–99 years of age, of 
whom 53% were female. Samples were grouped accord-
ing to collection date: pre–fi rst wave (before April 2009 
[1,403 samples]) and post–fi rst wave (August–October 
2009 [3,091 samples]); post–second wave (January–April 
2010 [2,225 samples]); and pre–third wave (June–Octo-
ber 2010 [1,782 samples]) and post–third wave (Febru-
ary–April 2011 [1,257 samples]) (Figure 1). Availability 
of samples by region and patient age was not consistent. 
With the objective of measuring age-dependent incidence, 
we prioritized serum samples by patient age. Samples were 
spread across 7 age groups (<5, 5–14, 15–24, 25–44, 45–
64, 65–74, and >75 years) and came from the 9 regions of 
England (East, East Midlands, London, North East, North 
West, South East, South West, West Midlands, and York-
shire and Humber).
Viruses were characterized and sequenced as de-
scribed (4). All samples were tested by hemagglutination-
inhibition (HI) assay; samples with suffi cient material also 
were tested by microneutralization assay according to stan-
dard methods (1). Samples with titers >32 or >40 by HI 
or microneutralization assay, respectively, were considered 
seropositive.
We determined antibody persistence by comparing an-
tibody levels in the post–second wave panel with those of 
the pre–third wave panel on a subset of samples from 3 
regions (North East, North West, and South West) where 
samples were available for both time points. Results were 
assessed with 95% confi dence intervals. The full analysis 
of the seroprevalence preceding the 2010–11 season is de-
tailed elsewhere (1).
In samples from all persons except those in the young-
est age group (<5 years), antibody declined from the end of 
the 2009–10 winter season (post–second wave) to before 
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Figure 1. Number of infl uenza A(H1N1)pdm09 virus detections 
(and percentage positive) detected through a network of Health 
Protection Agency laboratories (the Respiratory DataMart system) 
from the start of the pandemic in week 17 (week of April 27) 2009 
until the end of the 2010–11 winter season. It demonstrates the 
3 waves of pandemic infl uenza activity in summer 2009, autumn 
2009, and winter 2010–11 and the key events in relation to the 
timing of the national infl uenza vaccination program. The timing 
of the serum collections are illustrated at the bottom of the fi gure. 
Samples were grouped into panels according to their collection. 
Light gray, A(H1N1)pdm09 virus; medium gray, untyped infl uenza 
A virus; black, infl uenza B virus; line, overall percentage positive. 
Study periods were defi ned as follows: pre–fi rst wave, before April 
2009; post–fi rst wave, August–October 2009; post–second wave, 
January–April 2010; pre–third wave, June–October 2010; and 
post–third wave, February–April 2011. 
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the onset of the 2010–11 season (pre–third wave). This de-
cline was limited (<10% reduction by HI and microneu-
tralization assays in persons 5–74 years of age), with the 
largest reduction in the >75-year group (–15% and –20% 
by HI and microneutralization assays, respectively). In 
children <5 years, antibody levels increased (15% and 10% 
by HI and nicroneutralization assays, respectively) during 
the same time period (Tables 1,2; Figure 2).
We assessed changes in antibody levels during the 
2010–11 season using data from all 5 available regions 
(East, North East, North West, South West, and Yorkshire 
and Humber) (Tables 1, 2; online Technical Appendix Ta-
ble, wwwnc.cdc.gov/EID/pdfs/12-0720-Techapp.pdf). For 
all age groups, HI and microneutralization assays demon-
strated similar trends, although the increase by microneu-
tralization assay in elderly persons was lower than by HI 
assay (48% vs. 28% increase). We found no evidence for 
association of titer with sex or region.
Children in the 2 youngest groups (<14 years) had 
the highest titers overall and highest percentage of sero-
positive samples (Tables 1, 2; Figure 2; online Technical 
Appendix Table). The highest increases in seroprevalence 
during the third wave were observed in the oldest age 
group (>75 years, from 17% to 65% seropositive by HI 
assay), followed by young adults (15–44 years, from 33% 
to 66% seropositive by HI assay) (online Technical Ap-
pendix Figure).
Conclusions
Clinical surveillance data obtained during the course 
of acute illness (2) and seroepidemiology through popula-
tion sampling are consistent and together point toward a 
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Table 1. Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011* 
Characteristic
No. seropositive samples/no. total samples† (% seropositive samples, 95% CI) 
Post–second wave‡ Pre–third Post–third wave 
HI MN HI MN HI MN 
Age group, y       
 <5 36/98 (0.37, 
0.27–0.47) 
31/77 (0.4, 
0.29–0.52) 
94/182 (0.52, 
0.44–0.59) 
88/174 (0.51, 
0.43–0.58) 
99/160 (0.62, 
0.54–0.69) 
93/150 (0.62, 
0.54–0.7) 
 5–14 132/213 (0.62, 
0.55–0.69) 
69/107 (0.64, 
0.55–0.73) 
142/244 (0.58, 
0.52–0.64) 
152/237 (0.64, 
0.58–0.7) 
155/200 (0.78, 
0.71–0.83) 
146/199 (0.73, 
0.67–0.79) 
 15–24 68/154 (0.44, 
0.36–0.52) 
44/101 (0.44, 
0.34–0.54) 
152/405 (0.38, 
0.33–0.42) 
156/400 (0.39, 
0.34–0.44) 
216/320 (0.68, 
0.62–0.73) 
188/311 (0.6, 
0.55–0.66) 
 25–44 66/200 
(0.33, 0.27–0.4) 
31/83 (0.37, 
0.27–0.49) 
106/370 (0.29, 
0.24–0.34) 
114/370 (0.31, 
0.26–0.36) 
187/294 (0.64, 
0.58–0.69) 
155/283 (0.55, 
0.49–0.61) 
 45–64 59/220 0.27, 
0.21–0.33) 
42/110 (0.38, 
0.29–0.48) 
69/320 (0.22, 
0.17–0.26) 
93/318 (0.29, 
0.24–0.35) 
62/138 (0.45, 
0.36–0.54) 
52/135 (0.39, 
0.3–0.47) 
 65–74 36/145 
(0.25, 0.18–0.33) 
27/87 (0.31, 
0.22–0.42) 
35/168 (0.21, 
0.15–0.28) 
42/167 (0.25, 
0.19–0.32) 
38/74 (0.51, 
0.39–0.63) 
38/74 (0.51, 
0.39–0.63) 
 >75 55/172 (0.32, 
0.25–0.4) 
77/163 (0.47, 
0.39–0.55) 
16/93 (0.17, 
0.1–0.26) 
25/92 (0.27, 
0.18–0.37) 
46/71 (0.65, 
0.53–0.76) 
39/71 (0.55, 
0.43–0.67) 
Region§    
 Total 1,202 1,782 1,257 
 North West 561 624 337 
 South West 404 232 265 
 North East 237 526 179 
 East 0 292 122 
 Yorkshire and  
 Humber 
0 108 354 
*HI, hemagglutination inhibition assay; MN, microneutralization assay. 
†Samples with titers >32 by HI or >40 by MN, 
‡For data consistency, samples from only North West, South West, and North East regions were included in this analysis because these regions also 
were among the 5 regions in pre– and post–third wave samples. 
§Numbers by region describe total available number of samples (all analyzed at least by HI assay). 
Table 2. Seroincidence estimates of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011 
Age group, y 
Change in antibody level, % (95% CI) 
Post–second wave to pre–third wave* Pre–third wave to post–third wave† 
Hemagglutination inhibition Microneutralization Hemagglutination inhibition Microneutralization 
<5 15 (3–27) 10 (–3 to 24) 10 (0–21) 11 (1–22) 
5–14 –4 (–13 to 5) 0 (–11 to 11) 19 (11–28) 9 (1–18) 
15–24 –7 (–16 to 3) –5 (–15 to 6) 30 (23–37) 21 (14–29) 
25–44 –4 (–12 to 4) –7 (–18 to 5) 35 (28–42) 24 (16–31) 
45–64 –5 (–13 to 2) –9 (–19 to 1) 23 (15–33) 9 (0–19) 
65–74 –4 (–13 to 5) –6 (–18 to 6) 31 (18–43) 26 (13–39) 
>75 –15 (–25 to –4) –20 (–32 to –8) 48 (34–61) 28 (13–42) 
*Antibody levels at the end of the 2009–10 winter season compared with those before the 2010–11 season. 
†Antibody levels before and after the 2010–11 season. 
shift in the age range for infection with A(H1N1)pdm09 
in the fi rst season after the 2009 pandemic. This fi nding is 
similar to those in earlier pandemics (5) and other countries 
(6). Historical data, including from 1918, suggest that the 
initial impact in children is followed by a dramatic shift in 
age distribution of infected persons, with the probability of 
infection in adults exceeding those of children until the age 
distribution returns to the normal seasonal pattern (5,7). 
This adaptation process may take 3–10 years (7).
The rates of decline in antibody to A(H1N1)pdm09 
from the 2009–10 to the 2010–11 winters are similar to 
historic data (8) and A(H1N1)pdm09 vaccine trials (9,10). 
The implications of such reduction are uncertain. The se-
roprevalence data suggested susceptibility in young adults 
pre–third wave, but not in children who were targeted by 
an extended vaccination program in the United Kingdom 
from January 2010. Up to 30% of children <5 years were 
vaccinated (11).
During the 2010–11 season, antibody was acquired 
primarily by young and old adults. The largest increase 
in antibody levels after the 2010–11 winter occurred in 
persons >75 years of age. Clinical surveillance data sug-
gests that elderly persons (>65 years of age) were relatively 
spared from infection with A(H1N1)pdm09 virus (12). We 
propose that the increase resulted primarily from seasonal 
infl uenza vaccination in 2010–11 with vaccine uptake of 
72.8% (13). In young adults (15–44 years), we believe that 
acquisition of antibody occurred as susceptible persons be-
came infected during the winter. Children were relatively 
spared from infection with A(H1N1)pdm09 during winter 
2010–11; their high rate of infection in the 2 previous pan-
demic waves, together with vaccination, left a limited num-
ber of susceptible persons (Figure 2) .
Our study design—a retrospective, periodic, cross-
sectional collection—has certain limitations. We analyzed 
similar but not identical groups and persons at different 
time points. For each sample, only limited information was 
available. Without information about vaccination status or 
infl uenza exposure history during the season, our interpre-
tation of antibody levels and their changes has to be taken 
with caution. However, in this descriptive analysis we also 
used supportive evidence from UK infl uenza surveillance 
programs and take into account the date of vaccination tim-
ing and uptake, which strengthens our interpretation of the 
serologic data.
The collections for each sample set were distributed 
over time periods of up to 21 weeks, during which antibody 
levels would have changed, depending on the combined ef-
fects of seroconversion, antibody waning and availability of 
vaccination. A novel likelihood-based approach, described 
previously has therefore been developed to overcome some 
of the limitations of the conventional statistical method (1).
We found no evidence of substantial antigenic drift in 
circulating viruses that could affect seroepidemiology re-
sults (online Technical Appendix Table). We conclude that 
the intense A(H1N1)pdm09 virus activity in the England 
during the 2010–11 winter must have resulted from a com-
bination of factors.
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Figure 2. Percentage of samples with hemagglutination-inhibition titer >32 during 
consecutive waves of infl uenza activity, England, summer 2009 and 2009–10 and 
2010–11 infl uenza seasons. Data were plotted from all available results determined by 
hemagglutination-inhibition assay on samples from all regions. A) Children <5 years old. 
B) Children 5–14 years old. C) Persons 15–24 years old. D) Persons 25–44 years old. 
E) Persons 45–64 years old. F) Persons 65–74 years old. G) Persons >75 years old. 
Black line, results from all regions; gray line, results from the North West and South West 
regions, which provided samples throughout the entire period. Error bars indicate 95% 
confi dence intervals.
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The change in age distribution of infection is likely 
to have caused increased severity, resulting from a larger 
number of patients with underlying concurrent conditions 
(12) or from age-dependent changes in pathology. Defi ning 
antibody correlates of protection becomes more complex 
with rising patient age as other immune mechanisms in-
creasingly contribute to protection, e.g., CD4+ T cells, as 
demonstrated in human challenge experiments (14). More-
over, a murine model identifi ed the role of age in suscep-
tibility to pathogenesis and transmission of infl uenza virus 
infection (15). These observations might help to provide 
some mechanistic insights for the shift in age distribution 
of infection and severity in the season after the 2009 pan-
demic. Genetic drift in circulating virus over time affecting 
human airway adaptation and varying climatic conditions 
during different pandemic waves also should be investi-
gated.
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